A phase I open label dose escalation study of intravenous aflibercept (AVE0005, vascular endothelial growth factor (VEGF) Trap) in combination with R-CHOP [rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone +methotrexate] administered every 2 weeks or every 3 weeks in patients with non Hodgkin's B-cell lymphoma.

Trial Profile

A phase I open label dose escalation study of intravenous aflibercept (AVE0005, vascular endothelial growth factor (VEGF) Trap) in combination with R-CHOP [rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone +methotrexate] administered every 2 weeks or every 3 weeks in patients with non Hodgkin's B-cell lymphoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 May 2016

At a glance

  • Drugs Aflibercept (Primary) ; Cyclophosphamide; Doxorubicin; Methotrexate; Prednisone; Rituximab; Vincristine
  • Indications B cell lymphoma
  • Focus Adverse reactions; Biomarker
  • Sponsors Sanofi
  • Most Recent Events

    • 04 Jan 2012 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.
    • 04 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Mar 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top